Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”

por Pires, Antonio, Goyal, Kavitha, Greenspan, Andrew
Publicado 2018

Considerations for the US health-system pharmacist in a world of biosimilars

por Zlatkus, Andrea, Bixby, Todd, Goyal, Kavitha
Publicado 2020

Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab

por Yazici, Yusuf, Xie, Lin, Ogbomo, Adesuwa, Ellis, Lorie A, Goyal, Kavitha, Teeple, Amanda, Simsek, Ismail
Publicado 2018

A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population

por Yazici, Yusuf, Xie, Lin, Ogbomo, Adesuwa, Ellis, Lorie A, Goyal, Kavitha, Teeple, Amanda, Mutlu, Ece A, Simsek, Ismail
Publicado 2018

Ensuring Product Quality, Consistency and Patient Supply over Time for a Large-Volume Biologic: Experience with Remicade(®)

por Melsheimer, Richard, Calmann, Melissa, DeRitis, Albert, Philip, Vinod, Van Gog, Frank, Doolittle, Lawrence, Goyal, Kavitha, Neblock, Donald
Publicado 2018